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Abstract
Background: Recently, variations in a component of high-density lipoprotein (HDL), namely apolipoprotein M
(apoM), were found to be associated with chronic obstructive pulmonary disease (COPD). The aim of this study
was to evaluate the association between apoM and COPD severity. Factors associated with apoM, COPD, or
coronary artery disease (CAD) were also assessed.
Methods: A total of 110 COPD patients and 110 age- and sex-matched non-COPD controls were included. Among
them, thirty COPD patients and seven non-COPD controls had CAD. ApoM and pentraxin-3 levels were measured
by ELISA. Additionally, the levels of high-sensitivity C-reactive protein (hs-CRP), cholesterol, and triglyceride were
assessed using an automatic biochemical analyzer.
Results: Serum apoM levels increased gradually with COPD severity, with the most prominent apoM elevation
observed in very severe COPD cases. In addition, ApoM was correlated with percent-predicted forced expiratory
volume in one second (% predicted FEV1) (r = −0.38,
P < 0.001), low-density lipoprotein cholesterol (LDL-C) (r = 0.23, P < 0.017), and hs-CRP (r = 0.24, P = 0.01) in COPD
patients. Furthermore, apoM was shown to be a risk factor for COPD onset (OR = 1.095, 95 % CI = 1.034–1.160,
P = 0.002), but not associated with CAD in COPD patients.
Conclusions: Serum apoM was elevated in COPD patients and increased gradually with COPD severity. However,
there was no association between apoM and CAD development in COPD patients.
Keywords: Apolipoprotein M, Chronic obstructive pulmonary disease, Forced expiratory volume in one second,
% predicted FEV1, Cardiovascular disease
Background
Chronic obstructive pulmonary disease (COPD), the fourth
leading cause of morbidity and mortality worldwide, is
associated with significant economic and social burden [1].
An increasing number of COPD patients die from systemic
inflammatory complications, such as cardiovascular dis-
eases, rather than respiratory system failure [2, 3]. However,
the mechanisms linking systemic inflammation to cardio-
vascular diseases remain unclear and cannot simply be
explained by the effects of smoking or hypertension [3].
Apolipoprotein M (apoM) is a 26-kDa apolipoprotein
that belongs to the lipocalin protein superfamily. In the
serum, apoM mainly binds to high-density lipoproteins
(HDL). ApoM-HDL interactions promote pre-β HDL
formation [4] and increase cholesterol efflux from foam
cells [5]. Moreover, the anti-atherosclerotic properties of
apoM are attributed to its anti-inflammatory activity [6]
and protect low-density lipoprotein cholesterol (LDL-C)
against oxidation [7]. ApoM can potentially protect the
endothelium under homeostatic conditions [8] and sup-
press lymphopoiesis and neuroinflammation during the
adaptive immune response [9, 10].
The human apoM gene is located in the major histocom-
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also contains several genes involved in immune and inflam-
matory responses [11]. Recent studies suggested that a
number of inflammatory factors might be correlated with
increased serum apoM levels in COPD patients [12, 13].
Interestingly, serum and lung platelet-activating factor and
leptin levels are increased in COPD patients and corre-
lated with disease severity [14, 15], suggesting that the
systemic inflammation associated with COPD might cause
an increase in apoM expression. As part of the MESA
COPD study, Burkart et al. [16] recently reported that two
single nucleotide polymorphisms flanking the apoM gene
are associated with altered lung function. The latter study
also revealed that apoM mRNA is inversely associated
with the FEV1/FVC ratio [16].
The associations between apoM expression and markers
of inflammation remain unknown in COPD patients. We
hypothesized that serum apoM levels correlate with the
onset and severity of COPD. The main purpose of this
study was to assess the serum apoM level and determine
its clinical associations with lung function and inflamma-
tory markers in a cohort of patients with COPD at differ-
ent stages of disease severity.
Methods
Subjects
This was a case–control study of 110 COPD patients evalu-
ated at The Second Xiangya Hospital between July 2014
and June 2015. The diagnosis of COPD was based on each
patient’s clinical history, physical examination, chest radiog-
raphy, arterial blood gas measurements, and lung function,
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) 2015 classification [17]. Patients in
this study were classified as GOLD stages I/II (n = 32),
III (n = 39), and IV (n = 39).
The inclusion criterion was COPD patients with an
FEV1/FVC < 0.7. Exclusion criteria were: 1) body mass
index (BMI) >3 0 kg/m2; 2) history of pulmonary embolism;
3) metabolic acidosis; 4) immunological disease; 5) cancer;
6) venous or arterial thrombosis; 7) renal disease.
Coronary artery disease (CAD) was diagnosed by the
presence of stenosis on coronary angiography. Hyperten-
sion was defined as systolic blood pressure ≥ 140 mmHg
and/or diastolic blood pressure ≥ 90 mmHg. Diabetes mel-
litus was defined as fasting plasma glucose ≥ 7.0 mmol/L
and 2-h glucose tolerance test glucose > 11.1 mmol/L.
The control group included 110 age and sex matched
non-COPD volunteers who underwent physical examin-
ation in our hospital, with FEV1/FVC < 0.7 and a normal
chest X-ray.
The study protocol was reviewed and approved by
The Second Xiangya Hospital Investigational Review
Board. Written informed consent was obtained from all
participants.
Blood sampling
After an overnight fast and at least 20 min of rest, blood
samples were collected from each subject. Serum was
obtained by centrifugation at 3500 rpm for 5 min, and
aliquots were stored at −80 °C.
Enzyme-linked immunosorbent assay (ELISA) for apoM
assessment
Serum apoM levels were measured using a sandwich ELISA
(Yuan Tai Bio Inc., Changsha, Hunan, People’s Republic of
China). Optical density (OD) was measured at 450 nm
(with a background reading at 620 nm) on an ELX-800 ab-
sorbance reader (BioTek Instruments, Inc., Winooski, VT,
USA). The concentration of apoM (as mg/L) in each
sample was derived from a standard curve.
Lipoprotein and inflammation marker levels
Serum triglyceride, total cholesterol, HDL cholesterol
(HDL-C), LDL-C, apolipoprotein A (apoA), apolipoprotein
B (apoB), lipoprotein(a), and high-sensitivity C-reactive
protein (hs-CRP) levels were measured on an ARCHITECT
c8000 System (Abbott Laboratories, Irving, TX, USA).
Pentraxin-3 levels were detected using an ELISA kit
(CUSABIO, Wuhan, China) according to the manufac-
turer’s instructions.
Statistical analysis
Continuous data are presented as the mean ± standard
deviation; categorical data are expressed as percentages.
Continuous data were analyzed by Student’s t-test or
one-way analysis of variance (ANOVA) with Tukey’s test,
as appropriate. Variables with a skewed distribution were
converted by logarithmic transformation before analysis.
Pearson’s correlation analysis was used to assess the associ-
ations between the apoM level and normally distributed
variables. Spearman correlation analysis was used for vari-
ables with skewed distributions. Binary logistic regression
models were carried out to identify the risk factors for
COPD onset and identify the risk factors for CAD in
COPD patients. All analyses were performed with SPSS
20.0 (SPSS, USA) or GraphPad Prism 5.0 (GraphPad




Figure 1 depicts the patient flowchart. From 187 COPD
patients screened for participation, 32 did not meet the eli-
gibility criteria and 45 refused to participate; therefore, 110
patients were finally assessed. Additionally, 254 controls
were screened for participation; 45 failed the eligibility cri-
teria, 61 refused to participate, and 28 were eliminated by
the matching criteria; therefore, 110 were finally included.
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Age (67 ± 10 vs. 67 ± 10 years, P = 0.823), gender
(86 % vs. 86 % men, P = 0.99), and BMI (22.2 ± 2.3 vs.
22.2 ± 2.3 kg/m2, P = 0.954) were similar between the
COPD and control groups (Table 1) and across all
COPD GOLD stages (Additional file 1: Table S1). The
COPD group had a higher proportion of smokers (64 %
vs. 35 %, P < 0.001), CAD (28 % vs. 6 %, P < 0.001),
hypertension (25 % vs. 11 %, P = 0.008), and hormone
therapy (27 % vs. 0 %, P < 0.001) compared with the
control group. % predicted FEV1 and FEV1/FVC were
lower in COPD patients compared with control values
(P < 0.001). Pentraxin-3 levels were higher in COPD
patients compared with the control group (1.28 ± 2.66
vs. 0.96 ± 2.05 ng/L, P = 0.002).
Serum apoM amounts are elevated in COPD patients
Serum apoM levels in COPD patients were 23.08 ±
9.54 mg/L, higher than values obtained for healthy con-
trols (P < 0.0001; Table 1). The most pronounced apoM
increase in COPD patient subpopulations was observed in
GOLD stage IV, followed by stages III and I/II (P < 0.05;
Fig. 2).
Factors associated with apoM in COPD patients
The serum lipid profile and pulmonary function were
assessed for their associations with apoM using univariate
correlation analyses; % predicted FEV1 was used to evaluate
lung function. Interestingly, % predicted FEV1 was inversely
correlated with the serum apoM level (r = −0.38, P < 0.001;
Fig. 3a). ApoM was positively correlated with serum LDL-C
(r= 0.23, P = 0.017; Fig. 3b) and hs-CRP (r = 0.24, P = 0.01;
Fig. 3c). Marginally significant correlations were observed
between apoM and pentraxin-3 (r = 0.18, P = 0.06; Fig. 3d).
Risk factors for COPD onset
To identify the risk factors associated with the onset of
COPD symptoms, a binary logistic regression model of the
whole study population was built by initially including all
variables with P < 0.05 in univariate analyses (Table 1) and
systematically excluding variables that were not significant
(P > 0.10). Triglycerides (OR = 0.528, 95 % CI = 0.283–
0.985, P = 0.045) and HDL-C (OR = 0.292, 95 % CI = 0.101-
0.844, P = 0.023) were identified as protective factors. In
contrast, apoM (OR = 1.095, 95 % CI = 1.034–1.160,
P = 0.002), smoking history (OR = 2.542, 95 % CI = 1.188–
5.440, P = 0.016), and hs-CRP (OR= 1.249, 95 % CI =
1.136–1.374, P < 0.001) were found to be risk factors for
COPD onset in the final model (Table 2).
Risk factors for CAD in COPD patients
To identify the risk factors associated with CAD in
COPD patients, a binary logistic regression model was
performed. Non-significant variables (P > 0.05) were sys-
tematically excluded. Use of a β-2 adrenergic receptor
antagonist (OR = 0.179, 95 % CI = 0.040–0.804, P = 0.025)
was identified as a protective factor. In contrast, hyperten-
sion (OR = 2.018, 95 % CI = 1.380-2.952, P < 0.001) and
aminophylline use (OR = 7.048, 95 % CI = 2.169-22.906,
P = 0.001) were risk factors for CAD onset in COPD
patients (Table 3). In this model, apoM was not associ-
ated with the development of CAD in COPD patients.
Discussion
This study revealed a relationship between the serum apoM
level and % predicted FEV1, a gold standard for severity
assessment of airflow obstruction. These results extend the
findings of the MESA COPD study, which demonstrated
an inverse relationship between airflow obstruction and
apoM mRNA levels and suggested that serum apoM is a
predictor of COPD onset [16]. As shown above, serum
apoM was not associated with CAD in COPD patients. A
potential mechanism behind the high cardiovascular dis-
ease prevalence in COPD patients is the altered endothe-
lium function resulting from airflow obstruction [18].
Fig. 1 Patient flowchart
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Previous studies demonstrated that the type or degree of
endothelial damage in COPD patients might be involved in
the development of CAD [19, 20], but the exact
interrelationships of CAD, COPD, and apoM remain elu-
sive and require further investigation. Nevertheless, a previ-
ous study showed that apoM gene expression is inversely
correlated with the severity of COPD [16].
Previously, apoM was considered a negative acute re-
sponse protein [21]. ApoM gene expression is decreased in
systemic inflammation stimulated by lipopolysaccharides
(LPS), zymosan, or turpentine, as well as in patients with
sepsis [21, 22]. In this study, the apoM level was correlated
with the amount of hs-CRP, which is a marker of systemic
inflammation, but not with that of pentraxin-3, a marker of
acute-phase immune reactions [23]. Many reasons may
explain this discrepancy. The previous studies showing
decreased apoM gene expression after exposure to chemi-
cals or LPS were performed in an acute setting, using com-
pounds known to elicit a massive systemic inflammatory
response [21, 22]. In this study, the increased inflammatory
state was the result of a chronic state that might have differ-
ent mechanisms compared to the acute state [24]. In
addition, two different protective mechanisms involving
apoM take place under acute or chronic inflammatory
conditions. In response to acute inflammation, circulating
apoM is severely depleted upon binding to S1P and the
endothelium-protective S1P1 receptor; these interactions
prevent an increase in vascular permeability or leakiness
[8, 25]. On the other hand, in the process of chronic sys-
temic inflammation, apoM expression might be
Table 1 Demographic and biochemical parameters of the
study subjects
COPD Controls P value
Subjects, n 110 110
Demographics
Age, years 67 ± 10 67 ± 10 0.823
Sex, % male 86 86 0.847
Body mass index, kg/m2 22.2 ± 2.3 22.2 ± 2.3 0.954






CAD 28 6 <0.001
Hypertension 25 11 0.008
Diabetes mellitus 5 1 0.098
Treatment, %
Prednisone 27 0 <0.001




Anticholinergics 23 0 <0.001
Lung function
FEV1% predicted 43.81 ± 19.77 92.34 ± 8.29 <0.001
FEV1/FVC 49.44 ± 15.96 97.48 ± 3.73 <0.001
Lipids profile
Triglycerides, mmol/L 1.17 ± 0.67 1.43 ± 1.11 0.036
Total cholesterol, mmol/L 4.16 ± 0.82 4.49 ± 0.76 0.003
HDL-C, mmol/L 1.15 ± 0.30 1.31 ± 0.26 <0.001
LDL-C, mmol/L 2.50 ± 0.77 2.61 ± 0.70 0.285
Apolipoprotein A, g/L 1.36 ± 0.29 1.46 ± 0.27 0.011
Apolipoprotein B, g/L 0.89 ± 0.22 0.94 ± 0.27 0.122
Apolipoprotein M, mg/L 23.08 ± 9.54 17.02 ± 4.74 <0.001
Lipoprotein(a), g/L 163.9 ± 2.4 99.0 ± 9.3 <0.001
Inflammatory factors
Hs-CRP, mg/L 11.52 ± 3.97 1.47 ± 2.77 <0.001
Pentraxin-3, ng/L 1.28 ± 2.66 0.96 ± 2.05 0.002
Data are mean ± standard deviation. Values of triglycerides, lipoprotein(a), and
hs-CRP were converted into a logarithmic form before analysis. The p-values
refer to comparisons between the COPD and control groups
GOLD Global Initiative for Chronic Obstructive Lung Disease, COPD chronic
obstructive pulmonary disease, CAD coronary artery disease, HDL-C high-density
lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hs-CRP
high-sensitivity C-reactive protein, FEV1 forced expiratory volume in one second,
FVC forced vital capacity, NS non-significant
Fig. 2 Serum apolipoprotein M (apoM) is elevated in chronic obstructive
pulmonary disease (COPD) patients. Serum concentrations of apoM in
COPD patients, grouped according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stage, and healthy control subjects
(HC). Error bars represent the standard errors of the mean. *P< 0.05,
**P< 0.01 vs. HC. #P< 0.05, between two groups indicated by the
horizontal line
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compensated or even up-regulated to counteract inflam-
matory effects over a longer period of time as part of an
innate protective mechanism [26]. A previous study
showed that elevated apoM gene expression is associated
with lower FEV1/FVC [16], corroborating our findings.
Nevertheless, the present study was not designed to deter-
mine the the mechanisms that cause apoM elevation in
COPD patients, and additional investigations are needed
for this purpose. A previous study revealed elevated
pentraxin-3 in patients with obstructive sleep apnea and
increased carotid intima-media thickness [23], in agree-
ment with the present study; however, additional studies
are warranted to characterize the inflammatory response
in COPD patients and its relationship with atherosclerosis.
In this study, surprisingly, serum apoM was only associ-
ated with one lipid, LDL-C. Serum apoM reportedly shows
positive correlations with serum total cholesterol, LDL-C,
and HDL-C [7, 11]. This is particularly true for HDL-C, as
approximately 96 % of apoM is bound to HDL particles
[27]. In COPD patients, it is possible that apoM is readily
redistributed within the pool of serum lipoproteins, and this
occurs even though it is anchored to the surface of lipopro-
teins by its hydrophobic signal peptide [28]. ApoM was
shown to be exchanged from HDL-C to LDL-C because of
altered HDL-C amounts under inflammatory conditions
[29, 30]. Accordingly, in this study, HDL-C was lower in
COPD patients. On the other hand, LDL-C particles are
susceptible to oxidative modifications [31] and a decrease
in particle size [32] during infection and inflammation, all
of which increase the likelihood of their participation in the
Fig. 3 Associations of apoM and % predicted FEV1, LDL-C, hs-CRP, and Pentraxin-3. a Post-dilatation forced expiratory volume in one second, % predicted
FEV1, was correlated with apoM (r =−0.38, P < 0.001); and (b) low-density lipoprotein cholesterol (LDL-C) was correlated with apoM (r =0.23, P = 0.017). c
High-sensitivity C-reactive protein (hs-CRP) was associated with apoM (r= 0.24, P= 0.01). d Pentraxin-3 was not associated
with apoM (r= 0.18, P= 0.057)
Table 2 Binary logistic regression analysis for COPD
P value OR 95 % CI (OR)
Hs-CRP <0.001 1.249 1.136–1.374
Smoking history 0.016 2.542 1.188–5.440
Triglycerides 0.045 0.528 0.283–0.985
HDL-C 0.023 0.292 0.101–0.844
Apolipoprotein A 0.063 5.830 0.911–37.293
Apolipoprotein M 0.002 1.095 1.034–1.160
Note: High-density lipoprotein cholesterol was transformed to a dichotomous
variable according to its average value 1.24 mmol/L
COPD chronic obstructive pulmonary disease, hs-CRP high-sensitivity C-reactive
protein, HDL-C high-density lipoprotein cholesterol
Table 3 Binary logistic regression analysis for CAD in COPD
patients
P OR 95 % CI (OR)
Hypertension <0.001 2.018 1.380–2.952
Aminophylline use 0.001 7.048 2.169–22.906
β-2 adrenergic receptor antagonist use 0.025 0.179 0.040–0.804
COPD chronic obstructive pulmonary disease, CAD coronary artery disease
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development of atherosclerosis [33]. Indeed, small-sized
LDL-C particles (known as subclass pattern B) more
effectively cross the endothelial barrier [34] and are more
susceptible to oxidative modifications [35]. This could
result in a rapid uptake and accumulation of cholesterol in
macrophages and, consequently, contribute to the develop-
ment of atherosclerosis [36], which should be examined in
future studies.
Finally, the abnormal lipid profile observed in this
study suggests a high risk for cardiovascular diseases in
COPD patients. Indeed, HDL-C is inversely associated
with cardiovascular disease diagnosis [37, 38]; this is
attributed primarily to the role of HDL-C in the reverse
transport of cholesterol [39]. Increased Lp(a) is another
strong independent risk factor for CAD [40]. The inter-
action of Lp(a) with pro-inflammatory oxidized phospho-
lipids is thought to be atherogenic [41]. The decreased
HDL-C levels and increased Lp(a) levels observed in the
current study suggest an increased risk of cardiovascular in
COPD patients. Systemic inflammation is strongly associ-
ated with atherosclerosis [36] and might explain the high
risk of cardiovascular diseases associated with the patho-
logical process of COPD.
A few limitations of the present study should be men-
tioned. The main limitation is the disproportionate num-
ber of men included in the study population. Women
only accounted for 14 % of all subjects. A study design
with an approximately equal number of male and female
subjects would provide more conclusive results. Another
limitation is the relatively small number of COPD patients
with CAD. Additional studies with a larger sample size for
this COPD subpopulation will be necessary to elucidate
the possible role of apoM in cardiac function. In this
study, apoM was not associated with CAD when consider-
ing the use of drugs in the multivariate model. Longitu-
dinal studies could be particularly helpful in determining
the causal relationships of apoM, COPD, and CAD.
Conclusions
Serum apoM was elevated in COPD patients, and it in-
creased gradually with the stage of COPD severity. It was
also found to be an independent risk factor for COPD
development. There was no association between apoM and
the development of CAD in COPD patients.
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